

A black and white photograph of a modern, multi-story building with a light-colored, horizontally-ribbed facade. A large, white rectangular sign is mounted on the building, featuring the Inspiration Healthcare Group logo and name. The building has several windows, some with dark frames. A security camera is visible on the upper left side of the building. The sky is overcast. A large, dark blue circular graphic element is overlaid on the right side of the image, partially obscuring the building.

Inspiration Healthcare Group

FY27 Interim Results

October 27th 2026

Disclaimer

While the information contained herein has been prepared by Inspiration Healthcare Group plc (“Inspiration”) in good faith, neither it nor any of its directors, officers, agents, advisers, affiliates or employees makes any representation or warranty, express or implied, nor shall any of them have any responsibility whatsoever in respect of the accuracy or completeness of, or omissions from the contents of this document or any other document or information, written or oral, supplied at any time or in respect of any opinions or projections expressed herein or omitted therefrom.

No responsibility is accepted, and any and all responsibility and liability is expressly disclaimed, by Inspiration and its directors, officers, agents, advisers, affiliates or employees for any errors, miss-statements, misrepresentations or omissions in this document or any other such document or information supplied at any time to the recipient or its advisers in the course of the recipient’s evaluation of Inspiration.

Any forward-looking information contained in this document is based on subjective estimates and assumptions made by representatives of Inspiration and about circumstances and events that have not yet taken place. Such estimates and assumptions involve significant elements of subjective judgement and analysis which may or may not be correct. Accordingly, no representations are made as to the accuracy of such information and there can be no assurance that any such projected results will be attained, or outcome realised.

Neither Inspiration, nor any of its subsidiaries, affiliates, representatives, partners, directors, officers, employees, advisers or agents has any authority to make or give any representation or warranty whatsoever in relation to Inspiration or the prospects of Inspiration and makes no such representation or warranty.

This document does not constitute or form part of any offer for the sale of shares, business or assets of Inspiration nor shall it constitute the basis of any contract which may be concluded for the sale of the shares, business or assets of Inspiration.

Agenda

H1 FY27 Highlights

H1 FY27 Financial Review

Business Direction Short & Mid Term

Outlook and Q&A

Appendices



H1 FY27 Highlights

H1 FY27 in Summary

Operations

- Strong underlying growth ahead of market expectations
- SLE outperforming both in UK & Ireland and International – without impact of any large one-off orders
- Growth in Service revenues, solid performance in Asia-Pacific and growing in Western Europe with key wins
- Airon solid performance – large 3-year contract with US healthcare provider signed and delivered initial order, while sales pick up in International
- Ramped up production to fulfil demand with streamlined resources
- Transition of Infusion therapies distribution to Micrel underway – with sales performance on plan

Post Period

- Upgrade to FY Outlook, with momentum into FY28
- Credit approval received for renewal of RCF facility for a new 3-year term with option to extend

Product strategy

- Entry to US market is top priority of R&D, ongoing project continues with FDA filing expected late-'27, clearance H1 '28
- Re-positioning and launch of SLE1500 device geared at sub-acute care areas
- Consumables – projects on track for launches in Q4 FY27

Organisation

- Dedicated regional management for LatAm and Middle East & Africa recruited
- New CCO appointed in Q3 – ownership of all customer-facing functions
- Re-organisation of Service structure and leadership under commercial
- Efficiencies in operations through updated processes in all functions – revamped company ERP system
- Organisational streamlining launched in Q3 FY27

From Stabilisation to Performing



H1 FY27 Financials

H1 FY27 Financial Highlights

Revenue



£22.0m

(H1 FY26: £24.0m)

Underlying
Revenue¹



+26%

Gross
Margin



41.9%

(H1 FY26: 46.2%)

Adjusted
EBITDA²



£1.2m

(H1 FY26: £1.3m)

Inventory



£9.2m

(31 January 26: £8.8m)

Operating
Cash Flow



£2.7m

(H1 FY26 £3.6m)

Net
Debt³



£5.2m



(31 January 26: £5.1m)

¹ Underlying revenue excludes £6.5m one-off export orders in FY26

² Earnings before interest, tax, depreciation, amortisation, impairments, share based payments and non-recurring items

³ Cash and cash equivalents less revolving credit facility and invoice financing borrowings

H1 FY27 Revenue



Strong underlying growth 26% for the Group excluding impact of £6.5m one-off export projects

SLE Products underlying growth of 35%

- UK/Ire +32%
- International +37%

Inspiration Healthcare revenue +9% as Infusion products recovered from destocking in PY

Airon sales +40% with initial order from large US healthcare provider and international sales

Capital sales 69% of total SLE product revenues

Within SLE, service revenue +21%


H1 FY27 Income Statement

	H1 FY27 £'000	H1 FY26 £'000
Revenue	22,038	23,988
Gross Profit	9,242	11,091
<i>Gross margin</i>	41.9%	46.2%
Admin. expenses ex non-recurring items	(9,035)	(10,858)
Other income	136	-
Adjusted operating profit	343	233
Non-recurring items	292	(17)
Operating profit	635	216
Net finance expense	(354)	(500)
Profit/(loss) before tax	281	(284)
Income tax	(26)	22
Profit/(loss) after tax	255	(262)
Adjusted EBITDA¹	1,222	1,264

- Gross margin reduced from:
 - Loss of one-off capital sales of £6.5m in PY
 - Infusion products mix and selling price
 - Growth in lower price international markets
 - Increased costs from stockpiled components
- Operating expenses -17%
 - PY commissions paid on one-off export contracts - £1.0m
 - FX losses - £0.5m in PY
 - Ongoing cost control
- Non-recurring item credit from settlement on dilapidations liability at former Croydon site
- Net finance expense -29% on lower net debt
- EBITDA of £1.2m in line with PY despite lower revenue

¹ Earnings Before interest, tax, depreciation, amortisation, share based payments and non-recurring items.

H1 FY27 Movement in Net Debt



- Net debt stable at £5.2m
- Operating cash generation from EBITDA and ongoing working capital management
- Further inventory reduction of ~£2.0m expected in H2
- R&D investment of £2.1m linked to SLE6000 update for FDA and RoW and fees for new ventilator technology
- Lease and interest payments of £0.6m
- Credit approval received for renewal of RCF facility for a new 3-year term with option to extend, on existing terms, endorsing strength of core business



Business performance & direction

From 'Back to Basics' – To Growth & Leadership

Short-term – Strengthen the basics

Drive Sales

Re-engage with our distributors
Restructure UK sales and marketing
Deliver strong first year performance for Airon

Improve Profits

Improve operating efficiency
Reduce inventory – improve supply chain efficiency

Execute Strategy

Revisit vision, culture

Mid-term – Build for growth

Drive Sales

Drive international expansion – AsiaPac, LatAm
Support Europe – clinical presence
Marketing fundamentals
Launch of own consumables & service

Improve Profits

Improve operating efficiency
Strengthen supply mix

Execute Strategy

Define vision, culture and branding
Add clinical advisory board & leadership
Align portfolio

Long-term – Lead the market

Drive Sales

US neonatal market entry
Grow recurring revenue of consumables & service

Increase Profits

Focus on higher margin mix
Maintain stronger discipline

Execute Full Product Strategy

Deliver full neonatal roadmap – next generation products
Innovate with clinical leaders
Expand to adjacent segments

12

2024 H2

2025- 2026

2027 onwards

Three Business Units With Clear Focus

	1	2	3
	Neonatal Ventilation	Medtech Distribution	Specialty Ventilation
Brand			
Positioning	Global innovation leader in neonatal ventilation	UK/Ireland medtech distribution partner	Global champion in pneumatic ventilation
Portfolio	Neonatal ventilators, consumables & accessories incl. UK SLE sales	SLE vents, other neonatal products, jet ventilator excl. UK SLE sales excl. Infusion	Pneumatic ventilators, consumables & accessories
Target	FY25 ~£20m -> FY31 target: £45m Highest growth potential	FY25 ~£4m -> FY31 target: £8m Medium potential	FY25 £2.5m -> FY31 target: £5m Medium potential
Levers	1 US market entry and share gain 2 Share gain in EU countries 3 Own consumables range 4 Strengthen service business 5 Add other neonatal products	1 Growth through commercial focus, share gain in jet ventilation and transport incubators 2 Add other selected medtech products 3 Minimise non-profitable products	1 Strengthen US sales organization 2 Increase share in emergency segment 3 Grow international sales (ex-US)

From Performing to Doubling



FY27 priorities

- Growing funnel of opportunities in AsiaPac and LatAm, maintain MENA and Central Asia
- Share gain in Europe
- Launch of consumables range (Q1 and Q3)
 - Specific UK-focus programs
- Launch of Service-as-a-Product
- Growth of SLE1500 device sales
- Clinical marketing with opinion leaders
- Progress through FDA submission project in R&D
- New technologies to enhance product offering

H1 FY27 highlights

- Sales of £13.4m +35% vs H1 FY26 on underlying basis
- SLE now in every level 3 NICU in Ireland and market leader in HFO, also retain lead in UK
- Strong growth in international sales and opportunity pipeline continuing momentum into H2 and FY28
- Strong growth in Europe with sales £2.4m vs £1.2m in PY
- Service-as-a-product launched in UK driving growth in service revenues
- SLE consumables launching Q4
- Continue to assess new product opportunities

Delivering breaths in moments that matter



FY27 priorities

- Transition on Infusion Therapies to an entity controlled directly by the principal, Micrel
 - Transfer of personnel on July 1st 2026, with Micrel UK to manage commercial activities while building operational infrastructure
 - Invoicing through IHC till end of FY'27 with minimal impact to financial performance
- Full year of Monsoon 4 with very good funnel of opportunities
- Launch of new transport incubator
- Identification/potential onboarding of 3rd party products in Neonatal space to expand solution offering

H1 FY27 highlights

- Sales growth of 9% to £7.0m (H1 FY26: £6.4m)
- Infusion products recovery with sales of £5.5m (H1 FY26: £4.6m)
- Signed framework agreement with Micrel to transition Infusion therapy products to Micrel UK
- Monsoon 4 sales growing strongly with strong opportunity pipeline for H2 & FY28
- First order for new transport incubator received
- Continue to assess opportunities for additional 3rd party neonatal products

Advancing patient care together



FY27 priorities

- Execution of major contract of 150 devices, also driving future consumables sales
- Online sales portal operational and include consumables and capital
- Sales in international markets through existing SLE/Inspiration distribution network
- Increased marketing and access to Emergency services market, early mobility and major GPOs in the US
- Increased opportunities through 3rd party online sales portals

H1 FY27 highlights

- Sales grew 40% to £1.6m (H1 FY26: £1.1m)
- Delivered initial order of 150 devices to leading US healthcare provider
- Run rate of consumable sales increasing
- Sales into SLE international markets starting
- Access to major GPOs progressing
- Re-engaged with legacy distributors in hospital and emergency services markets expanding commercial reach

Giving breath to the world

A circular inset image showing medical equipment with several corrugated tubes connected to a device, likely a ventilator or respiratory system.

Growth of SLE

Grow SLE Globally – Total Solution Provision in Neonatal Ventilation

Back to Basics
24-25

1
Sales &
Marketing
Excellence

2
Operational
Efficiency

3
Supply Chain,
Inventory

4
Organisational
efficiency

► *Customer
focus*

Focus on Core
26-27

1
US market
penetration

2
Expansion in EU
countries

3
Own
consumables

4
Strengthen
service
business

► *Growth &
Profitability*

Innovate & Lead
28 ->

1
Address Full
Care
Pathway


2
Innovative
Therapies

3
Decision Support
Tools

4
Global Presence

► *Leadership*

Grow SLE Globally – Longer term: Total Solution in Neo Ventilation



Devices		★ ★	★ ★	★ ★	★ ★	Technology acquisition opportunity
Consumables		★	★	★	★	Launch of own consumables
Decision Tools		★	★	★ ★	★	Clinical partnerships & studies
Education		★ ★	★ ★	★ ★	★ ★	Clinical marketing
Services		★ ★	★ ★	★ ★	★ ★	Launch of SaaS

★ Current offerings
★ Future goal



Outlook and Q&A

H2 Outlook – FY27 Revenue to be at least £43m

Positive outlook

- H1 FY27 demonstrates strength of core SLE business without benefit of one-off large orders
- Orderbook and opportunity pipeline provide confidence in FY27 revenues of at least £43m and momentum continuing into FY28 and beyond
- Service revenue momentum and launch of SLE consumables to drive recurring revenue growth
- Further working capital improvement with inventory reduction expected in H2

Operational and organisational changes

- Internal reorganisation to set business up for post Infusion exit
- Further cost savings initiative underway in H2

Short and Mid-term product roadmap on track, focusing on:

- Product enhancements
- Own consumables launches
- US market access
- Continuing search for additional neonatal products to broaden portfolio


It's All About Execution!



Thank you

Appendix

Inspiration Healthcare Group History



Build on the strong legacy of three brands



Inspiration Healthcare Group – Serving Three Distinct Markets

Inspiration Healthcare designs, manufactures and markets pioneering medical technology that saves lives and improves the outcomes of patients starting with the very first breath of life

Neonatal Intensive Care (approx. 65% revenue)

Serviceable addressable market
£325m
Neonatal ventilation CAGR ~6%

- Own Brand capital and consumable products with IP
- Distribute complementary products
- Direct sales in UK, Ireland
- Global sales into >75 countries
- UK service centre
- In-house R&D
- State-of-the-art manufacturing centre in South London

Specialty ventilators (approx. 6% revenue)

- Own Brand capital and consumable products with IP
- Manufacturing & Service centre in US
- US sales through national distribution partner & direct sales

Infusion Therapies (approx. 29% revenue)

- Distribution of market leading products
- UK and Ireland sales & support
- UK service centre

Broad Portfolio of Innovative, Specialist Products

Key Neonatal Products



First Breath™ nCPAP

Inspire nCPAP™

Inspire rPAP™



Breathing Circuits



SLE Ventilators

Neonatal

- Core focus area with a high level of expertise
- Products designed specifically for the neonate with benefits such as OxyGenie™, The Queen's Award-winning auto-O₂ software
- Manufactured products are supported by complementary distributed technology providing us with a comprehensive offering
- Approx 70% capital, 30% recurring revenue

Key Airon Products



pNeuton Model A



pNeuton Mini

Airon

- Fully pneumatic ventilators with unique applicability in transport and MRI environments
- Adult and neonatal versions
- Approx 70% capital, 30% recurring revenue

Neonatal Care

Neonatal Intensive Care: A Growing Core Market Despite Changing Dynamics

Global Growth Drivers



Increase in healthcare infrastructure



Increase in premature births



Technology advancements



Increase in Affordability

Changing Market Dynamics

- Saturation in adult ventilation market driving new entrants resulting in more aggressive competition in neonatal segment
- Increased regulation slowing new markets penetration
- Increased macro-economic uncertainty affecting government healthcare investment



Every year, an estimated 15 million babies are born preterm^{1,2} and this number is rising³



Neonatal Intensive Care⁴
\$7.7bn with a CAGR of 6.46%



~£1,500 cost per baby per day in neonatal intensive care

Notes:


(1) Before 37 completed weeks of gestation

(2) Global, Regional & National estimates of levels of preterm birth 2014 – Chawanpaiboon et al 2019

(3) Global, regional, and national causes of under-5 mortality in 2000-15 – Liu L et al 2016

(4) Berkshire Hathaway 2022. Worldwide Neonatal Intensive Care Unit Industry is expected to grow with a CAGR of 6.46% from 2021 to 2027


Neonatal ICU Environment



Source for the photo: Neonest Hospital, India

Competitive Landscape in Neonatal Space

Not exhaustive,
work in progress



Grow SLE Globally – Total Market for Neo Ventilation is ~\$460m

Numbers rounded

Neo Ventilators

SLE: 7-8% share FY25

Neo Cons. & Access.

SLE: <3% share FY25



Global market size in value of ventilators sold in 2024

~\$200m



Global market size in value of C&A sold in 2024

~\$260m



Global market size in number of ventilators sold in 2024

~10'000



Number of patients treated in 2024

~3.2m



CAGR of global market size in value for period 2024-30

4-5%



CAGR of global market size in value for period 2024-30

4-5%



Average global end-user price per ventilator in 2024

~\$20'000



Average value of C&A used per ventilator per year

~\$2'400



Global installed base of ventilators in use in 2024

120'000




Average value of C&A used per patient

~\$80

SLE share '24 <10% → Plenty of room for growth

Grow SLE Globally – Opportunity: US Market Expansion



- Market is dominated by pure neonatal ventilators i.e., Draeger & Getinge. It is also served by ICU vents and Jet / HFO devices.
- Strong US market players, Medtronic & GE Healthcare, are winding down their ventilation offering thus leaving a vacuum to be filled.



- It is **perfect timing for SLE to penetrate the US market** as Medtronic & GE Healthcare are leaving behind unmet demand.
- SLE can aim to capture 10–20% of US market share **in 3–5 years term** with **expected revenue of 10–20m\$** for devices + consumables + service
- Need to set up a dedicated sales channel potentially with a **strategic partner or distributor**

Pure neonatal ventilators



Dräger
Babylog



GETINGE *
Servo-n

ICU derivative ventilators



HAMILTON MEDICAL
C1 neo



NIHON KOHDEN
OrangeMed
NKV-550

Jet / High frequency osc.



bunnell
gentle ventilation
LifePulse 204



ZOLL
3100A HFOV

Discontinued ventilators



Medtronic
PB840



GE HealthCare
CS R860

Inspiration Healthcare

UK&I Distribution Partner

Inspiration Healthcare – Products

Distributed Products



Monsoon Jet Ventilator – specialised surgeries



Gas Blenders



Consumables



Sucrose

Own products



rPAP generator – resuscitation support



Thermoregulation consumables

Specialty Ventilation

Airon Pneumatic Ventilators

Specialty Ventilators – Airon

Global Growth Drivers



Unique pneumatic technology ideal for transport and MRI



Synergies with core neonatal ventilation segment



Gain foothold in US with various manufacturers exiting the segment due to varied reasons

Market Opportunities



Leverage IHC global distribution network to increase footprint



Expansion into new therapy areas: Transport, Emergency Services



Capital linked to consumables